Red Eagle Mining appoints Michael Johnson Vice President Exploration

Red Eagle Mining Corporation (RD)

Joe’s Jeans Inc. (JOEZ)

Joe’s Jeans Announces Launch of a New Brand Exclusive to Macy’s

LOS ANGELES, CA–(Marketwire -02/29/12)- After more than a decade as a premium denim leader, Joe’s Jeans Inc. (NASDAQ: JOEZ – News) announces the launch of a new brand, else™, to be sold exclusively at Macy’s. With price points starting at $68, else™ was created to reach young women who are looking for a premium denim-like product at a more affordable price.

Macy’s has dedicated space in its Impulse departments in 140 stores throughout the U.S. to showcase the else™ brand. The new line will also be available at macys.com. The else™ product offering, which includes five staple denim fits: skinny, boot cut, cropped, boyfriend and a cuffed short, will be rolling out at Macy’s over the next two weeks.

Marc Crossman, President and CEO of Joe’s Jeans Inc., commented, “We are thrilled to be partnering with such a distinguished American institution. We look forward to an exciting and expansive business venture and the opportunity to create a unique product offering for the Macy’s customer.”

The else™ target customer is described as between the ages of 18 and 25 years old with a strong sense of self and fashion. Joe Dahan, Creative Director and Founder of Joe’s Jeans Inc., oversees the design of else™ with a newly created design team working in collaboration with Macy’s.

“We are excited to work with Joe’s Jeans to continue to bring our customer the latest in denim fashion by an industry leader with a long-standing commitment to fit and quality,” said Tim Baxter, Senior Vice President of Macy’s Women’s Division. Mr. Baxter continued, “else™ offers innovative products at an affordable price for our young, fashion-forward customers who will love this brand.”

About Joe’s Jeans Inc.

Joe’s Jeans Inc. designs, produces and sells apparel and apparel-related products to the retail and premium markets under the Joe’s® brand and related trademarks. In addition, the Company has introduced the else™ line for exclusive sale at Macy’s. More information is available at the company website at www.joesjeans.com.

This release contains forward-looking statements within the meaning of the safe harbor provision of the Private Securities Litigation Reform Act of 1995, as amended. The matters discussed in this document involved estimates, projections, goals, forecasts, assumptions, risks and uncertainties that could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. All statements in this news release that are not purely historical facts are forward-looking statements, including statements containing the words “intend,” “believe,” “estimate,” “project,” “expect” or similar expressions. Any forward-looking statement inherently involves risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to: the risk that the Company will be unsuccessful in gauging fashion trends and changing customer preferences; continued acceptance of the Company’s brands in the marketplace; successful implementation of any growth or strategic plans; the risk that changes in general economic conditions, consumer confidence, or consumer spending patterns will have a negative impact on the Company’s financial performance or strategies; the highly competitive nature of the Company’s business in the United States and internationally and its dependence on consumer spending patterns, which are influenced by numerous other factors; the Company’s ability to respond to the business environment and fashion trends; effective inventory management; the level of the Company’s cash flows, which will be impacted by the level of consumer spending and retailer and consumer acceptance of its products; the ability to generate positive cash flow from operations; competitive factors, including the possibility of major customers sourcing product overseas in competition with our products; the risk that acts or omissions by the company’s third party vendors could have a negative impact on the company’s reputation; a possible oversupply of denim in the marketplace; and other risks. The Company discusses certain of these factors more fully in its additional filings with the SEC, including its last annual report on Form 10-K and quarterly report on Form 10-Q filed with the SEC, and this release should be read in conjunction with those reports, together with all of the Company’s other filings, including current reports on Form 8-K, made with the SEC through the date of this release. The Company urges you to consider all of these risks, uncertainties and other factors carefully in evaluating the forward-looking statements contained in this release.

Any forward-looking statement is based on information current as of the date of this document and speaks only as of the date on which such statement is made, and the Company undertakes no obligation to update these statements to reflect events or circumstances after the date on which such statement is made. Readers are cautioned not to place undue reliance on forward-looking statements.

Alimera Sciences, Inc. (ALIM) Announces Positive Outcome to the European Decentralized Procedure for Approval of ILUVIEN

Alimera Sciences Announces Positive Outcome to the European Decentralized Procedure for Approval of ILUVIEN(R) for the Treatment of Chronic Diabetic Macular Edema

• ILUVIEN^(R) expected to be the first sustained release pharmaceutical in the European Union to treat diabetic macular edema (DME)
• ILUVIEN expected to be indicated for chronic DME considered insufficiently responsive to available therapies

ATLANTA, Feb. 28, 2012 (GLOBE NEWSWIRE) — Alimera Sciences, Inc., (Nasdaq:ALIM – News) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced the positive outcome of the Decentralized Procedure (DCP) for ILUVIEN(R) in Europe. The announcement follows the issuance of the Final Assessment Report from the Reference Member State (RMS), the Medicines and Healthcare products Regulatory Agency of the United Kingdom (MHRA), and the agreement of all the Concerned Member States (CMS) that ILUVIEN is approvable.

The regulatory process will now enter the national phase of the DCP in which the RMS and each CMS grants its national license. The CMS include Austria, France, Germany, Italy, Portugal and Spain. ILUVIEN will be indicated for the treatment of vision impairment associated with chronic DME considered insufficiently responsive to available therapies.

The International Diabetes Federation estimates that, in these seven countries alone, 22.1 million people are currently living with diabetes. By comparison, the Centers for Disease Control and Prevention estimate that Americans with diabetes now number 25.8 million. Alimera estimates that within the seven CMS countries, 1.2 million people suffer from DME.

“Achieving a favorable conclusion for ILUVIEN in Europe is a significant milestone for Alimera and very encouraging for the many patients with this challenging chronic disease,” said Dan Myers, president and chief executive officer, Alimera Sciences. “We will continue to work closely with the UK and the Concerned Member States to ensure that ILUVIEN is made available to patients as soon as possible.”

ILUVIEN is Alimera’s sustained release intravitreal implant that releases sub-microgram levels of fluocinolone acetonide (FAc) for up to 36 months for the treatment of chronic DME. The clinical trial data showed that in patients with chronic DME at month 30, after receiving the ILUVIEN implant, 38 percent of patients experienced an improvement from baseline in their best corrected visual acuity on the Early Treatment of Diabetic Retinopathy Study (ETDRS) eye chart of 15 letters or more. At the completion of the 36-month study, 34 percent had achieved the same result. This effect was highly statistically significant as compared to the sham control group, which received laser and other intravitreally administered therapies.

“Our market research indicates that, given DME is a leading cause of blindness in working-age adults, there is a significant opportunity for an effective ophthalmic drug to treat patients insufficiently responsive to available therapies,” said Dave Holland, senior vice president of sales and marketing, Alimera Sciences. “An effective, truly long-term treatment option could have a very positive impact on the quality of life for patients with this chronic debilitating disease.”

About ILUVIEN^(R)

ILUVIEN (190 micrograms fluocinolone acetonide intravitreal implant in applicator) is a sustained release intravitreal implant used to treat chronic DME. Each ILUVIEN implant provides a therapeutic effect of up to 36 months by delivering sustained sub-microgram levels of fluocinolone acetonide (FAc). ILUVIEN is inserted in the back of the patient’s eye to a position that takes advantage of the eye’s natural fluid dynamics. The applicator employs a 25-gauge needle, which allows for a self-sealing wound.

In July 2010, the Marketing Authorization Application (MAA) was submitted to seven European countries via the DCP with the UK MHRA as the RMS. The MAA included data from two Phase 3 pivotal clinical trials (collectively known as the FAME(TM) Study) for ILUVIEN conducted by Alimera. The trials involved 956 patients in sites across the United States, Canada, Europe and India to assess the efficacy and safety of ILUVIEN for the treatment of DME. Based on a consensus arrived upon by the RMS and the CMS, the MHRA issued its Final Assessment Report that ILUVIEN is approvable.

About FAME(TM) Safety

Safety was assessed among those patients treated with ILUVIEN who were in the subgroup of patients with DME for three years or more and were considered to have chronic DME. Intraocular pressure (IOP) increases to 30 millimeters of mercury (mmHg) or greater at any time point were seen in 12.7% of these patients by month 36, compared to 18.4% in the full ILUVIEN treated patient population. By month 36, 3.6% of these patients had undergone an incisional surgical procedure to reduce elevated IOP, compared to 4.8% in the full patient population. The incidence of cataracts among patients with a natural lens in their eye at the start of the study was 84.1% at month 36, with 87.3% undergoing a cataract operation, compared to 81.7% and 80%, respectively, in the full patient population.

About DME

DME, the primary cause of vision loss associated with diabetic retinopathy, is a disease affecting the macula, the part of the retina responsible for central vision. When the blood vessel leakage of diabetic retinopathy causes swelling in the macula, the condition has progressed to DME. The onset of DME is painless and may go undetected by the patient until it manifests with the blurring of central vision or acute vision loss. The severity of this blurring may range from mild to profound loss of vision. As the population of people with diabetes increases, it is anticipated that the annual incidence of diagnosed DME will increase.

About Alimera Sciences, Inc.

Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Presently Alimera is focused on diseases affecting the back of the eye, or retina. Its primary product, ILUVIEN, is an intravitreal implant containing fluocinolone acetonide (FAc), a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease.

Forward Looking Statements

This press release contains “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, regarding, among other things, Alimera’s future results of operations and financial position, business strategy and plans and objectives of management for Alimera’s future operations. Words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “contemplate,” “predict,” “project,” “target,” “likely,” “potential,” “continue,” “will,” “would,” “should,” “could,” or the negative of these terms and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The events and circumstances reflected in Alimera’s forward-looking statements may not occur and actual results could differ materially from those projected in its forward-looking statements. Meaningful factors which could cause actual results to differ include, but are not limited to, delay in or failure to obtain regulatory approval of Alimera’s product candidates, uncertainty as to Alimera’s ability to commercialize (alone or with others), and market acceptance of, its product candidates, the extent of government regulations, uncertainty as to relationship between the benefits of Alimera’s product candidates and the risks of their side-effect profiles, dependence on third-party manufacturers to manufacture Alimera’s product candidates in sufficient quantities and quality, uncertainty of clinical trial results, limited sales and marketing infrastructure, inability of Alimera’s outside sales force to successfully sell and market ILUVIEN in the U.S. following regulatory approval and Alimera’s ability to operate its business in compliance with the covenants and restrictions that it is subject to under its credit facility, as well as other factors discussed in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Alimera’s Annual Report on Form 10-K for the year ended December 31, 2010, and Quarterly Report on Form 10-Q for the quarter ended September 30, 2011, which are on file with the Securities and Exchange Commission (SEC) and available on the SEC’s website at www.sec.gov. Additional factors may also be set forth in those sections of Alimera’s Annual Report on Form 10-K for the year ended December 31, 2011 to be filed with the SEC. In addition to the risks described above and in Alimera’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the SEC, other unknown or unpredictable factors also could affect Alimera’s results. There can be no assurance that the actual results or developments anticipated by Alimera will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Alimera. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved. 

All forward-looking statements contained in this press release are expressly qualified by the cautionary statements contained or referred to herein. Alimera cautions investors not to rely too heavily on the forward-looking statements Alimera makes or that are made on its behalf. These forward-looking statements speak only as of the date of this press release (unless another date is indicated). Alimera undertakes no obligation, and specifically declines any obligation, to publicly update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise

Tibet Pharmaceuticals, Inc. Announces Intent to Go Private

NEW YORK, Feb. 27, 2012 /PRNewswire-Asia/ — Tibet Pharmaceuticals, Inc. (NASDAQ: TBET – News), an emerging specialty pharmaceutical company engaged in the development, manufacturing and marketing of traditional Tibetan medicine in China, today announced that,

“In recent days, we noticed that a website mentioned about auctioning our operating entity’s assets. These were untrue and incorrect announcements. Our company is in normal business operation. We’re conducting our investigation on this mistaken report, and will keep our investors informed on the investigation result,” said Mr. Hong Yu, CEO and Chairman of Tibet Pharmaceuticals. “The Company will take all necessary legal measures to defend itself against any untrue reports and to protect the interests of shareholders.”

The Company also announced its intent to accept a “going private” proposal by Mr. Hong Yu, and cease its public company status. “In view of market bias towards Chinese companies listed in U.S. stock exchange and our past stock performance, I hereby make an offer to purchase TBET stocks not owned by me for $3.00 per share in cash,”said Mr. Hong Yu, “delisting details will be announced shortly”.

Tibet Pharmaceuticals expects to continue to grow in China’s fragmented pharmaceutical and traditional Tibetan medicine industries. The company is committed to establishing itself as a leading manufacturer and distributor of Tibetan medicine in China and believes that additional distribution channels will help enhance its completive advantages in the industry.

About Tibet Pharmaceuticals, Inc.

Based in Shangri-La County, Yunnan Province, China, Tibet Pharmaceuticals, Inc. (NASDAQ: TBET – News) is an emerging specialty pharmaceutical company engaged in the research, development, manufacturing and marketing of modernized traditional Tibetan medicines in China. With 190 employees and nation-wide distributors, the company develops both prescription and over-the-counter traditional Tibetan medicines that promote health in human respiratory, digestive, urinary and reproductive systems. Tibet Pharmaceuticals’ products are sold throughout China, with a majority of sales concentrated in the southern provinces, most notably Yunnan Province, where the company’s 52,000 sq. ft. GMP-certified manufacturing facilities are located. The access to key raw materials, not generally available outside the province, provides a significant advantage for Tibet Pharmaceuticals.

For comprehensive investor relations material, including fact sheets, research reports, presentations and video, please follow the appropriate link: White Paper, Investor Portal and Overview Video.

For more information on Tibet Pharmaceuticals, please visit:
http://www.tibetpharmaceuticals.com/

Forward-Looking Statements

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts.

These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, changes in company valuations and investor perceptions of companies, and other risks contained in reports filed by the company with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

North American Potash Developments Inc. Acquires Potassium Sulfate/Alunite Property in Santa Cruz, Arizona

North American Potash Developments Inc. (NPD)

North American Potash Developments Inc. (NPD)

Something you may want to take a look at and keep a watch on this week , towards the end of last week NPD.V Looks to be setting up and it looks like its finally ready to go ,Trading in the 20 X 23c range Testing 0.24 on Friday with nice volume. weak resistance at 0.27 could quite possibly hit 0.33 ,

Chart Link
http://stockcharts.com/h-sc/ui?s=NPD.V&p=D&b=5&g=0&id=p98586944209

North American Potash Developments Inc., holds State Leases for potash properties covering 6,277

acres and 24,640 acres in prospecting permits applications in Utah’s Paradox Basin and State Mineral

Permits for 15,994.32 acres in the Holbrook Basin in Arizona.

Given the strong demand for agricultural products, experts predict that there will be a strain on supply,

keeping price for potash relatively strong for the foreseeable future.

Pacific Ethanol, Inc. (PEIX)

Pacific Ethanol, Inc. to Present at the Bank of America Merrill Lynch 2012 Global Agriculture Conference

SACRAMENTO, Calif., Feb. 24, 2012 (GLOBE NEWSWIRE) — Pacific Ethanol, Inc. (Nasdaq:PEIX – News), the leading marketer and producer of low-carbon renewable fuels in the Western United States, is scheduled to present at the Bank of America Merrill Lynch 2012 Global Agriculture Conference in Bal Harbour, Florida on Wednesday, February 29, 2012 at 10:45 a.m. Eastern Time. Neil Koehler, president and chief executive officer, will discuss Pacific Ethanol’s business strategy.

The presentation will be available live via webcast on Pacific Ethanol’s website at www.pacificethanol.net. A replay will be available for a period of 90 days thereafter.

About Pacific Ethanol, Inc.

Pacific Ethanol, Inc. (Nasdaq:PEIX – News) is the leading marketer and producer of low-carbon renewable fuels in the Western United States. Pacific Ethanol also sells co-products, including wet distillers grain (WDG), a nutritional animal feed. Serving integrated oil companies and gasoline marketers who blend ethanol into gasoline, Pacific Ethanol provides transportation, storage and delivery of ethanol through third-party service providers in the Western United States, primarily in California, Nevada, Arizona, Oregon, Colorado, Idaho and Washington. Pacific Ethanol has a 34% ownership interest in New PE Holdco LLC, the owner of four ethanol production facilities. Pacific Ethanol operates and manages the four ethanol production facilities, which have a combined annual production capacity of 200 million gallons. The facilities in operation are located in Boardman, Oregon, Burley, Idaho and Stockton, California, and one idled facility is located in Madera, California. The facilities are near their respective fuel and feed customers, offering significant timing, transportation cost and logistical advantages. Pacific Ethanol’s subsidiary, Kinergy Marketing LLC, markets ethanol from Pacific Ethanol’s managed plants and from other third-party production facilities, and another subsidiary, Pacific Ag. Products, LLC, markets WDG. For more information please visit www.pacificethanol.net.

The Pacific Ethanol, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=5940

TAKEDOWN ENTERTAINME (TKDN.OB)

Takedown Entertainment Appoints George Chung as VP Distribution

BELLUS Health reports results for year ended December 31, 2011, and provides update on KIACTA™ phase 3 confirmatory study

Company Plans Expansion of Study to Japan

LAVAL, QC, Feb. 22, 2012 /CNW Telbec/ – BELLUS Health Inc. (TSX: BLU.TO – News) (“BELLUS Health” or the “Company”) reported today its financial results for the year ended December 31, 2011, and provided an update on its pipeline of products.

Highlights

• Japanese Pharmaceutical and Medical Device Agency (PMDA-Japan) has accepted sponsor’s proposal to expand the KIACTA™ phase 3 confirmatory trial to Japan;
• Continued enrolment of patients in the KIACTA™ phase 3 registration trial;
• Turned VIVIMIND™ business cash-flow positive in 2011;
• Further expanded VIVIMIND™’s marketing and sales network through license agreements in new markets;
• Completed phase 1 trial of NRM8499: the compound was found to be safe and well tolerated at the intended therapeutic dose;
• Completed several strategic initiatives that reduced use of cash and extended the Company’s financial resources to mid-2013.

“During 2011, BELLUS Health continued to execute on its business plan, making significant progress on several fronts,” said Roberto Bellini, President and Chief Executive Officer of BELLUS Health. “In particular, the expansion of the KIACTA™ phase 3 registration trial to Japan is an important milestone for the Company and now positions KIACTA™ for marketing approval in the three major global pharma markets, the United States, Europe and Japan, on completion of the phase 3 study,” Mr. Bellini added.

KIACTA™ (eprodisate) for the treatment of AA amyloidosis – During 2011, BELLUS Health and its strategic partner Celtic Therapeutics (“Celtic”) continued the patient recruitment for the global phase 3 confirmatory clinical trial for KIACTA™ (eprodisate). The trial is designed to confirm the safety and efficacy of KIACTA™ in preventing renal function decline in patients diagnosed with AA amyloidosis. The international, randomized, double-blind, placebo-controlled, event-driven study will involve approximately 230 patients diagnosed with AA amyloidosis recruited from 83 sites in 28 countries worldwide, including those in Japan. Thus far, a total of 72 clinical centers in 26 countries are actively recruiting patients. The Japanese portion of the study is scheduled to enroll 10-20 patients in up to seven clinical centers. These sites are expected to be activated in the second half of 2012 and will recruit patients for at least one year. Recruitment is ongoing and is expected to be completed in the second half of 2013.

The phase 3 confirmatory study is an event-driven trial which will conclude when 120 patients have reached worsening events linked to deterioration of kidney function. Further to the expansion of the study to Japan and the extension of the recruitment period, the completion of the study is now expected in the second half of 2015.

There will be periodic data safety monitoring review boards that will independently assess the safety of KIACTA™ (eprodisate) throughout the study. The first such monitoring review board is scheduled to convene in April 2012. No efficacy interim analysis will be performed.

KIACTA™ (eprodisate) has been granted Orphan Drug Designation in the United States and received Orphan Medicinal Product designation in Europe, which normally provide for market exclusivity of seven years and ten years, respectively, once the drug is approved. KIACTA™ (eprodisate) has also received Orphan Drug Designation in Switzerland.

VIVIMIND™, a natural health product designed to protect memory function – Following the agreements entered into in 2010 relating to the distribution of VIVIMIND™ in Italy with FB Health LLC (“FB Health”), and the exclusive license and supply agreement for the distribution of VIVIMIND™ in Canada with Advanced Orthomolecular Research Inc. (“AOR”), the Company entered into an exclusive license and distribution agreement with Agahan Ayandeye Pars Inc. (“Agahan Group”) in 2011 for the rights to VIVIMIND™ in Egypt, United Arab Emirates, Pakistan, Iran and certain other Gulf states. The Agahan Group expects to launch VIVIMIND™ in the first half of 2012. The Company also entered into an exclusive license and distribution agreement with Integris Pharma Ltd. (Integris) in 2011, who has secured the exclusive right to market and sell VIVIMIND™ in Greece and Cyprus. Integris expects to launch VIVIMIND™ in Greece and Cyprus in the middle of 2012.

The Company is actively pursuing additional partnerships in order to further expand VIVIMIND™’s commercial footprint throughout the world.

NRM8499, a prodrug of tramiprosate for the treatment of Alzheimer’s disease - In January 2011, BELLUS Health announced the results of the phase I clinical trial for NRM8499, which investigated the safety, tolerability and pharmacokinetic profile of NRM8499 as compared to tramiprosate in a group of 67 young and elderly healthy subjects. The phase I clinical trial data demonstrated that NRM8499 was safe and well tolerated at the intended therapeutic dose. Moreover, the gastrointestinal tolerability and pharmacokinetic profile of tramiprosate were meaningfully improved with NRM8499. The Company is currently exploring strategic partnership opportunities with the aim of further pursuing the development process of NRM8499.

Strategic Cost Reduction Initiatives Since the second quarter of 2010, the Company has been implementing costs reduction initiatives to reduce its fixed-cost base and extend its financial resources. These included the reduction of the Company’s head count by more than 75%; the early termination of the lease agreement for the Company’s Laval, Quebec premises; and the reorganization of its international structure. As a result, the Company has significantly reduced its required cash outflows.

In early 2011, the Company exercised its right to terminate the lease of its Laval, Quebec premises as of April 7, 2011, as provided in the amended lease agreement dated March 31, 2009, with A.R.E. Quebec No. 2, Inc., the landlord of such premises. The early termination of the lease resulted in annual savings of approximately $4.5 million for the Company, representing a total of approximately $43 million in aggregate savings over the remainder of the original lease term. The Company has signed a new lease that began on April 8, 2011, at the same premises, for less space.

In 2011, BELLUS Health completed a corporate reorganization whereby the Company streamlined its international structure by liquidating its subsidiaries in Europe and the United States. The reorganization resulted in the repatriation of BELLUS Health’s intellectual property to Canada and the reduction of the Company’s operating expenses by approximately $1.4 million per year.

Financial Results All currency figures reported in this press release, including comparative figures, are in CDN dollars, unless otherwise specified.

For the year ended December 31, 2011, net income amounted to $3,424,000 ($0.01 per share), compared to a net loss of $24,553,000 ($0.12 per share) for the same period last year. For the fourth quarter ended December 31, 2011, the Company recorded a net loss of $2,223,000 ($0.01 per share), compared to $12,739,000 ($0.06 per share) for the corresponding quarter the previous year.

The increase in net income/decrease in net loss in the current periods, compared to the corresponding periods the previous year, is partly due to cost reduction initiatives implemented by the Company during the past years, such as reducing its workforce, amending and early terminating its lease agreement and streamlining its international structure. In addition, net income for the year ended December 31, 2011, includes finance income of $13,105,000 recorded in relation to the decrease in the fair value of the embedded conversion option liability on the 2009 Notes, compared to finance costs of $5,904,000 for the corresponding period in 2010. Net loss for the fourth quarter ended December 31, 2011, includes finance costs of $243,000 in relation to the increase in the fair value of the embedded conversion option liability on the 2009 Notes, compared to finance costs of $9,405,000 for the corresponding period in 2010.

As at December 31, 2011, the Company had available cash and cash equivalents of $5,105,000, compared to $10,257,000 as at December 31, 2010. For the year ended December 31, 2011, net decrease in cash and cash equivalents amounted to $5,152,000, compared to $3,760,000 for the corresponding period the previous year. The net decrease in 2010 is net of proceeds of $10.2 million received in relation to the KIACTA™ asset sale and license agreement entered into with Celtic in 2010. Excluding this cash inflow, net decrease in cash used compared to last year is attributable to cost reduction initiatives implemented by the Company, as discussed previously.

The Company’s consolidated financial statements and accompanying Management’s Discussion and Analysis for the year ended December 31, 2011, will be available shortly on SEDAR at www.sedar.com and on the Company’s web site at www.bellushealth.com.

Going Concern As at December 31, 2011, based on current estimates, the Company’s cash and cash equivalents on hand and expected sources of funds are considered, in management’s view, to be sufficient to meet its committed cash obligations and expected level of expenditures into the third quarter of 2013. Beyond that, the ability of the Company to continue as a going concern is dependent upon raising additional financing through borrowings, share issuances, receiving funds through sale of assets, supply agreements or product licensing agreements, and from obtaining regulatory approval in various jurisdictions to market and sell its product candidates and ultimately achieving future profitable operations. The outcome of these matters is dependent on a number of factors outside of the Company’s control. This material uncertainty may cast significant doubt about the Company’s ability to continue as a going concern beyond that period.

Management continues to pursue additional sources of funds including through further arrangements relating to the distribution of VIVIMIND™ and a potential partnership for NRM8499. While the discussions could lead to the signing of binding agreements in the future, there can be no assurance whatsoever that any such transaction will be put in place.

About BELLUS Health

BELLUS Health is a development-focused health company concentrating on the development of products that provide innovative health solutions and address critical unmet medical needs. For further information on BELLUS Health, please visit www.bellushealth.com.

Forward Looking Statements Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements.  Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond BELLUS Health Inc.’s control. Such risks include but are not limited to: the ability to obtain financing immediately in current markets, the impact of general economic conditions, general conditions in the pharmaceutical and/or nutraceutical industry, changes in the regulatory environment in the jurisdictions in which the BELLUS Health Inc. does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation, achievement of forecasted burn rate, achievement of forecasted clinical trial milestones, and that actual results may vary once the final and quality-controlled verification of data and analyses has been completed. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. The reader should not place undue reliance, if any, on any forward-looking statements included in this news release. These statements speak only as of the date made and BELLUS Health Inc. is under no obligation and disavows any intention to update or revise such statements as a result of any event, circumstances or otherwise, unless required by applicable legislation or regulation. Please see the Company’s public fillings including the Annual Information Form of BELLUS Health Inc. for further risk factors that might affect the Company and its business

FuelCell Energy Announces Cooperation With Fraunhofer IKTS

FuelCell Energy Announces Cooperation With Fraunhofer IKTS to Develop the European Market for Stationary Fuel Cell Power Plants

The Cooperation Will Target Opportunities in Europe for Ultra-Clean Baseload Power From Stationary Fuel Cell Power Plants Using Clean Natural Gas and Renewable Biogas

DANBURY, Conn., Feb. 22, 2012 (GLOBE NEWSWIRE) — FuelCell Energy, Inc. (Nasdaq:FCEL – News), a leading manufacturer of ultra-clean, efficient and reliable fuel cell power plants, today announced a memorandum of understanding to form a German-based joint venture with Fraunhofer IKTS (Institute for Ceramic Technologies and Systems) to develop the market in Europe for Direct FuelCell(R) (DFC(R)) stationary power plants. Additionally, Fraunhofer IKTS will contribute certain assets and their expertise in fuel cells and materials science to the joint venture.

“Germany needs clean baseload distributed power generation and FuelCell Energy has market leading solutions so it is a very good fit for Fraunhofer to work with FuelCell Energy,” said Prof. Dr. Alexander Michaelis, director, Fraunhofer IKTS. “The Fraunhofer IKTS team looks forward to applying our materials science and fuel cell expertise to help develop a broader range of applications and markets for FuelCell Energy products and technology.”

The joint venture will target the European market for baseload distributed generation from a location in Germany to address the trend towards clean and renewable decentralized power generation. The attributes of stationary fuel cell power plants can help European countries diversify their power generation portfolio and reach sustainability goals as they provide continuous ultra-clean power in a highly efficient process at the point of use. The power generation portfolio of many European countries includes intermittent renewable power generation. Continuous baseload power from stationary fuel cell plants will help balance this intermittency.

“Fraunhofer IKTS brings world-renowned applied research expertise and a vast network of relationships that will help to develop and grow a stationary fuel cell market in Germany, which will then provide a platform for expansion throughout Europe,” said Chip Bottone, President and Chief Executive Officer for FuelCell Energy, Inc. “We expect that the combination of complementary knowledge and skill sets of fuel cell technology between our respective organizations is going to be very powerful for further enhancing the performance of Direct FuelCell power plants.”

“Strong partners like German-based Fraunhofer IKTS and our recent partnership announcement with Spanish-based Abengoa are helping us execute our European strategy to penetrate and rapidly grow stationary fuel cell installations in Europe,” continued Mr. Bottone. “We have an active pipeline of approximately 45 megawatts in Europe developed in just the past year with limited local presence to date, illustrating the strong market potential.”

FuelCell Energy will lead market development and servicing efforts for Direct FuelCell power plants as well as support for existing carbonate fuel cell power plants already operating in Europe. Fraunhofer IKTS will contribute research & development resources for enhancing DFC technology and use local knowledge and relationships to assist in market development. FuelCell Energy has established a legal entity in Germany for the joint venture and will retain majority ownership.

There are a number of existing incentives in Europe for stationary fuel cell power plants operating on either clean natural gas or renewable biogas. In Germany for example, a feed-in tariff is promoting adoption of combined heat and power (CHP) power generation as the German government is targeting 25 percent of electricity generation to include CHP by 2020, up from the current level of 15 percent. Additional incentives are available that are specific to fuel cell power generation.

DFC power plants generate electricity and usable high quality heat with an electrochemical reaction that emits virtually no pollutants. Avoiding the emission of NOx, SOx and particulate matter supports clean air regulations and benefits public health. The high efficiency of the fuel cell power generation process reduces fuel costs and carbon emissions, and producing both electricity and heat from the same unit of fuel drives economics while simultaneously promoting sustainability. Fuel cells can achieve up to 90 percent efficiency when configured to use the high quality heat generated by the power plant in a combined heat & power (CHP) mode.

Ultra-clean, efficient and reliable DFC plants can help solve the power generation challenges facing European countries. For example, Germany is targeting a 40 percent reduction in carbon emissions, doubling power generation from renewable sources to 35 percent, and aiming to eliminate nuclear power generation by 2022, which accounts for approximately one quarter of existing power generation. DFC power plants are fuel flexible, capable of operating on clean natural gas or renewable biogas. Germany, for example, has an extensive natural gas distribution network, supporting on-site power markets as well as utility grid support.

Founded in 1949, Fraunhofer is Europe’s largest application-oriented research organization with an annual research budget of EURO1.8 billion (approximately $2.3 billion) and more than 18,000 staff, primarily scientists and engineers. Fraunhofer has research centers and representative offices in Europe, USA, Asia and the Middle East, and more than 80 research units, including 60 Fraunhofer Institutes, at different locations in Germany.  The Fraunhofer IKTS with its staff of 400 highly educated engineers, scientists and technicians is a world leading institute in the field of advanced ceramics for high tech applications. The primary markets for IKTS include energy and environmental technology with a focus on fuel cell development and commercialization.

Website: www.ikts.fraunhofer.de/en

The Fraunhofer IKTS logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=11748

About FuelCell Energy

Direct FuelCell(R) power plants are generating ultra-clean, efficient and reliable power at more than 50 locations worldwide.  With over 180 megawatts of power generation capacity installed or in backlog, FuelCell Energy is a global leader in providing ultra-clean baseload distributed generation to utilities, industrial operations, universities, municipal water treatment facilities, government installations and other customers around the world.  The Company’s power plants have generated more than one billion kilowatt hours of ultra-clean power using a variety of fuels including renewable biogas from wastewater treatment and food processing, as well as clean natural gas.  For more information, please visit our website at www.fuelcellenergy.com

The FuelCell Energy, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=3284

This news release contains forward-looking statements, including statements regarding the Company’s plans and expectations regarding the continuing development, commercialization and financing of its fuel cell technology and business plans. All forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors that could cause such a difference include, without limitation, general risks associated with product development, manufacturing, changes in the regulatory environment, customer strategies, potential volatility of energy prices, rapid technological change, competition, and the Company’s ability to achieve its sales plans and cost reduction targets, as well as other risks set forth in the Company’s filings with the Securities and Exchange Commission. The forward-looking statements contained herein speak only as of the date of this press release. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statement to reflect any change in the Company’s expectations or any change in events, conditions or circumstances on which any such statement is based.

Direct FuelCell, DFC, DFC/T, DFC-H2 and FuelCell Energy, Inc. are all registered trademarks of FuelCell Energy, Inc. DFC-ERG is a registered trademark jointly owned by Enbridge, Inc. and FuelCell Energy, Inc